MedCity News September 19, 2021
The startup, which has a cleared device to reduce tremors using electrical stimulation, recently shared the results of a post-market analysis showing device use and efficacy.
After getting de novo clearance for its device from the Food and Drug Administration in 2018, Cala Health touted data from a post-market analysis that it hopes will prove the device’s benefit to insurers.
The Burlingame, Calif.-based startup has a wearable device to help patients with essential tremor manage their symptoms.
The condition is characterized by involuntary shaking of the hands, and can affect people’s quality of life, including their ability to write, eat, and speak. Beta blockers are sometimes prescribed as a treatment, but not everyone tolerates the side effects well.
Cala’s...
Today's Sponsors
Today's Sponsor